INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA COX New | Government Relations Director |
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
Health Issues HCR
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA COX New | Government Relations Director |
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
Medicare/Medicaid MMM
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA COX New | Government Relations Director |
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
Budget/Appropriations BUD
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration, and global programs for various infectious diseases related issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA COX New | Government Relations Director |
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
Medical/Disease Research/Clinical Labs MED
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA COX New | Government Relations Director |
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.